Literature DB >> 29299365

HER-2/neu gene amplification in gastric adenocarcinoma and its relationship with clinical and pathological findings.

Ramin Azarhoosh1, Rokhsare Ebneghasem2, Sima Besharat3.   

Abstract

BACKGROUND: Amplification of the HER-2/neu oncogene influences the progression of gastric cancer, its prognosis, and therapy. A precise examination of HER-2/neu-amplified tumor tissue is essential for managing disease and prescribing the appropriate treatment. This study aimed to investigate the status of HER-2/neu gene in the gastric cancer samples and its relationship with clinical and pathological information.
METHODS: In this study on 80 paraffin-embedded tissue samples from patients with gastric adenocarcinoma [2006-2011], DNA was extracted to quantify the gene expression levels of HER-2 using a polymerase chain reaction (PCR) method. Data were statistically analyzed by chi-square test using SPSS16.0 software.
RESULTS: PCR results indicated that HER-2/neu gene amplifications occurred in 58 of the 80 samples (72.5%). HER-2/neu gene expression was not significantly related to age and sex, but the larger tumor size and the more advanced stage were significantly associated with HER-2/neu overexpression.
CONCLUSIONS: The data show the HER-2/neu gene is more amplified in stage 4 of gastric cancer with a larger size of mass. Older age and male sex also appear to be more associated with HER-2/neu gene expression.

Entities:  

Keywords:  Gastric adenocarcinoma; HER-2/neu amplification; polymerase chain reaction (PCR)

Year:  2017        PMID: 29299365      PMCID: PMC5750194          DOI: 10.21037/jgo.2017.10.11

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  21 in total

Review 1.  Gastric cancer in Ardabil, Iran--a review and update on cancer registry data.

Authors:  Masoud Babaei; Farhad Pourfarzi; Abbas Yazdanbod; Mir Mehdi Chiniforush; Mohammad Hassan Derakhshan; Seyed Mohsen Mousavi; Fatemeh Samadi; Giti Rahimi
Journal:  Asian Pac J Cancer Prev       Date:  2010

2.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

3.  Trend analysis of gastric cancer incidence in Iran and its six geographical areas during 2000-2005.

Authors:  Mohmmad Haidari; Mohammad Reza Nikbakht; Yahya Pasdar; Farid Najaf
Journal:  Asian Pac J Cancer Prev       Date:  2012

4.  Gastric cancer: epidemiology and risk factors.

Authors:  Guenter J Krejs
Journal:  Dig Dis       Date:  2010-11-18       Impact factor: 2.404

5.  The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.

Authors:  M S Al-Moundhri; V Nirmala; I Al-Hadabi; K Al-Mawaly; I Burney; M Al-Nabhani; V Thomas; S S Ganguly; C Grant
Journal:  J Surg Oncol       Date:  2005-09-15       Impact factor: 3.454

6.  Genetic analysis of HER-2/neu gene amplification in paraffin embedded tumour tissue in women with breast cancer.

Authors:  Marek Zadrozny; Beata Smolarz; Hanna Romanowicz-Makowska; Elzbieta Kozłowska; Andrzej Kulig
Journal:  Pol J Pathol       Date:  2002       Impact factor: 1.072

7.  Ets regulation of the erbB2 promoter.

Authors:  G K Scott; C H Chang; K M Erny; F Xu; W J Fredericks; F J Rauscher ; A D Thor; C C Benz
Journal:  Oncogene       Date:  2000-12-18       Impact factor: 9.867

8.  Telomere dysfunction provokes regional amplification and deletion in cancer genomes.

Authors:  Rónán C O'Hagan; Sandy Chang; Richard S Maser; Ramya Mohan; Steven E Artandi; Lynda Chin; Ronald A DePinho
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

Review 9.  Gastric cancer in Iran: epidemiology and risk factors.

Authors:  Reza Malekzadeh; Mohammad H Derakhshan; Zinab Malekzadeh
Journal:  Arch Iran Med       Date:  2009-11       Impact factor: 1.354

Review 10.  Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment.

Authors:  H C Hurst
Journal:  Breast Cancer Res       Date:  2001-10-01       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.